Sage Therapeutics, Inc.

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2

Sage Therapeutics, after a year of disappointing readouts from its clinical-stage pipeline, received an acquisition offer earlier in January from its Zurzuvae (zuranolone) partner Biogen and the compa

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

January’s J.P. Morgan Healthcare Conference should set the tempo for biotech and pharma companies over the year as mergers and acquisitions along with early announcements of full-year 2024 financials